Photodynamic therapy tested in vitro on cancer cell lines
December 2017
Oslo University Hospital, Oslo, Norway(1)
University of Oslo, Oslo, Norway(2)
University of Oslo, Oslo, Norway(2)
5-Fluorouracil (5-FU) is one of the standard chemotherapy drugs used to treat pancreatic cancer. However, treatment only extends survival modestly, and disease recurrence is typical due to drug resistance. CD105 (Endoglin) is a cell-surface glycoprotein whose level is elevated in tissues undergoing active angiogenesis, such as regenerating and inflamed tissues or tumours. The expression of CD105 on tumour-associated blood vessels makes CD105 an interesting target for therapy. Photochemical internalization (PCI) is a drug delivery technology for local and light controlled cytosolic release of therapeutics confined in the illuminated area only. In the present study, the researchers used in vitro experiments conducted on pancreatic cancer lines to show the feasibility of photodynamic therapy by sensitizing the cells to FU treatment and a controlled release of a CD105 antibody. This novel approach could be used as a dual anti-angiogenesis and anti-tumor cell strategy for cancer therapy.
5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin
Pål Kristian Selbo(1), Kaja Lund(2)
Added on: 09-15-2021
[1] https://jeccr.biomedcentral.com/articles/10.1186/s13046-017-0662-6[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
